CD274 and non-small cell lung carcinoma: Hence, we identified all 1,103 eligible NCT03061305 patients [with 1,229 total chemotherapy, anti-PD-(L)1, or chemotherapy + anti-PD-(L)1 therapy lines] from the SCMD who were in one of five relevant tumor types: NSCLC, H&N, EGC, SCLC, and TNBC (Supplementary Fig. S2; Fig. 4A); anti-PD-(L)1 (with or without chemotherapy) lines used in IRS discovery or validation were specifically excluded.